2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, Rossetti S, Davidsohn M, Eid M, Zarif T, McClure H, Spinelli G, Damassi A, Murianni V, Vauchier C, Oliveira T, Malgeri A, Modesti M, Mestre R, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E, Group S. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study. Clinical Genitourinary Cancer 2024, 22: 102185. PMID: 39217072, DOI: 10.1016/j.clgc.2024.102185.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetate plus prednisoneAndrogen deprivation therapyCancer-specific survivalCastration-sensitive prostate cancerFirst-line therapyProstate cancerAdverse eventsFailure of androgen deprivation therapyMedian cancer-specific survivalCastration-resistant prostate cancerAcetate plus prednisoneInternational multicenter registryMedian Follow-UpKaplan-Meier methodFirst-line treatmentUpfront docetaxelDeprivation therapyAbiraterone acetatePrimary endpointSurvival outcomesMulticenter registryADT+DFollow-up
2023
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized disease
2022
Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up
Chahoud J, Zacharias N, Pham R, Qiao W, Guo M, Lu X, Alaniz A, Segarra L, Martinez-Ferrer M, Gleber-Netto F, Pickering C, Rao P, Pettaway C. Prognostic Significance of p16 and Its Relationship with Human Papillomavirus Status in Patients with Penile Squamous Cell Carcinoma: Results of 5 Years Follow-Up. Cancers 2022, 14: 6024. PMID: 36551510, PMCID: PMC9775956, DOI: 10.3390/cancers14246024.Peer-Reviewed Original ResearchPenile squamous cell carcinomaCancer-specific survivalSquamous cell carcinomaOverall survivalLymphovascular invasionCell carcinomaMedian cancer-specific survivalHigh-risk human papillomavirusHR-HPV statusMedian overall survivalTumor p16 statusHuman papillomavirus (HPV) statusHigh-risk HPVIndependent prognostic factorSingle-institution analysisClinico-pathologic variablesIHC staining patternSitu hybridization kitHR-HPVHPV statusPatient characteristicsPrognostic factorsSpecific survivalMultivariable analysisPrognostic significance
2021
Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma.
Monsrud A, Avadhani V, Mosunjac M, Flowers L, Krishnamurti U. Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma. Archives Of Pathology & Laboratory Medicine 2021, 146: 1094-1101. PMID: 34936703, DOI: 10.5858/arpa.2021-0169-oa.Peer-Reviewed Original ResearchConceptsAnal squamous cell carcinomaPD-L1 expressionHIV viral loadTumor proportion scorePD-L1Squamous cell carcinomaOverall survivalCD4 countPrognostic factorsHIV statusViral loadCell carcinomaProportion scoreInvasive anal squamous cell carcinomaMedian cancer-specific survivalIndependent adverse prognostic factorDeath ligand 1 (PD-L1) expressionCancer-specific survivalAdverse prognostic factorLigand 1 expressionSignificant prognostic factorsDeath ligand 1Kaplan-Meier curvesWorse overall survivalLog-rank test
2020
PD-L1 Expression is Associated with Poorer Survival in Anal Squamous Cell Carcinoma: Analysis from an Urban Public Hospital
Monsrud A, Avadhani V, Mosunjac M, Krishnamurti U. PD-L1 Expression is Associated with Poorer Survival in Anal Squamous Cell Carcinoma: Analysis from an Urban Public Hospital. American Journal Of Clinical Pathology 2020, 154: s66-s67. DOI: 10.1093/ajcp/aqaa161.145.Peer-Reviewed Original ResearchMedian cancer-specific survivalAnal squamous cell carcinomaPD-L1 expressionSquamous cell carcinomaCancer-specific survivalHIV viral loadPD-L1 positive statusPD-L1Cell carcinomaOverall survivalSpecific survivalHIV statusViral loadCD4 countPositive statusPD-L1 negative casesPD-L1 positive casesPD-L1 positive groupInvasive squamous cell carcinomaPositive PD-L1Cancer-specific deathSignificant prognostic factorsKaplan-Meier curvesWorse overall survivalLog-rank test
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply